Diffuse Large B-cell Lymphoma
Conditions
Keywords
Lymphoid neoplasms, Loncastuximab, Rituximab, Roflumilast, Lo-RR-CHOP, R-CHOP
Brief summary
This study is developed by the investigator and is a, phase I, single arm, clinical trial that will enroll subjects with untreated diffuse large B-cell lymphoma (DLCBL) at high risk for poor outcome. The types of treatments given will be shared with participants. The aims are: 1. To assess the safety and how well the participants tolerate the treatment 2. Assess the response of the tumor to treatment to estimate complete response 3. Assess the response of the tumor to treatment to estimate progression-free survival
Detailed description
Exploratory analyses include cell free DNA (cfDNA). Each subject's disease will be biologically characterized at baseline. Enrolled subjects will receive 2 cycles of chemotherapy free therapy composed of loncastuximab 0.15 mg/kg, rituximab 375 mg/m2, and roflumilast 500 ug po daily; followed by 6 cycles of chemoimmunotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) at standard of care (SOC) doses, in combination with loncastuximab and roflumilast 500 ug po daily. Loncastuximab at a dose of 0.075 mg/kg will be added to other chemoimmunotherapy agents only for the first three (3) out of six (6) cycles. All subjects will have PET-CT at four time points during the trial: 1) screening, 2) cycle 3 (after the 2 initial chemotherapy free cycles of therapy), 3) cycle 6 (after 3 cycles of loncastuximab, roflumilast and R-CHOP), and 4) at end of therapy (EOT) after completing a total of eight cycles of treatment planned for the trial (two chemotherapy free and six of chemoimmunotherapy). All subjects will have cfDNA monitoring at three time points during the trial: 1) cycle 1 day 1 (baseline), 2) cycle 3 day 1 (after the 2 initial chemotherapy free cycles of therapy), and 3) at end of therapy (EOT) after completing a total of eight cycles of treatment planned for the trial (two chemotherapy free and six of chemoimmunotherapy). Responses will be evaluated by PET-CT as per Lugano response criteria1 and correlated with cfDNA analysis. Cycles are 21 days long.
Interventions
DRUGLoncastuximab
Intravenous (IV) administration 0.15 mg/kg day 1 cycles 1-2, and 0.075mg/kg day 1, cycles 3-5
DRUGRoflumilast
Oral administration of 500mcg days 1-21, cycles 1-8
DRUGRituximab
IV administration of 375mg/m2 day 1, cycles 1-8
DRUGCyclophosphamide
IV administration of 750mg/m2 day 1, cycles 3-8
DRUGVincristine
IV administration 1.4mg/m2 (max 2mg) day 1, cycles 3-8
DRUGDoxorubicin
IV administration 50mg/m2 day 1, cycles 3-8
DRUGPrednisone
Oral administration 100mg/days 1-5, cycles 3-8
Sponsors
The University of Texas Health Science Center at San Antonio
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Phase I, single arm, open label clinical trial that
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Men and women 18 years of age or older. 2. Pathologically proven diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS). \- Patients with Diffuse large B-cell lymphoma/ high grade B-cell lymphoma with MYC (myelocytomatosis oncogene) and BCL2 (B-cell lymphoma 2) rearrangements are allowed. 3. No prior systemic therapy for lymphoma. 4. Subject has provided informed consent. 5. Subject is willing and able to comply with clinic visits and procedure outlined in the study protocol. 6. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. 7. Life expectancy of ≥3 months. 8. Ann Arbor stage II-IV 9. National Comprehensive Cancer Network - International Prognostic Index (NCCN-IPI) risk score of ≥ 2 10. Measurable disease, meaning at least 1 lymph node or other lymphomatous lesion with a long axis of ≥1.5 cm by CT imaging, and at least one FDG-avid lesion by FDG-PET scan. 11. Left ventricular ejection fraction of at least 45% by either echocardiography or radionucleotide angiography. 12. Ability to swallow oral tablets without difficulty. 13. All subjects with preserved reproductive potential must agree to practice abstinence or employ contraceptive measures for the duration of treatment and for 10 months (if female) or 7 months (if male) following final dosing. All male subjects are considered to have reproductive potential. Female subjects of reproductive potential are those who: i) are not at least 50 years old and have no menses for 24 consecutive months; or ii) have not been rendered surgically sterile (having undergone hysterectomy and/or bilateral salpingo-oophorectomy). Female subjects of reproductive potential must have a negative serum pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin (hCG) within 7 days of first day of drug dosing. 14. Meet the following clinical laboratory requirements: * Creatinine clearance ≥30 ml/min by Cockcroft-Gault formula; * Total bilirubin ≤ 1.5 × upper limit of normal (ULN) (unless indirect bilirubin is elevated due to Gilbert's syndrome or hemolysis); * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT)≤ 3 × ULN; * Platelet count ≥ 50,000/µL, with or without transfusion support; * Absolute Neutrophil Count (ANC) ≥ 1000/µL, with or without chronic granulocyte growth factor support; * Hemoglobin ≥8 g/dL, with or without transfusion support.
Exclusion criteria
1. Allergy or intolerance to roflumilast. 2. Allergy or intolerance to loncastuximab 3. Any active malignancy other than DLBCL 4. Current participation in another interventional clinical study 5. Prior allogeneic bone marrow transplant within 12 months of screening date. 6. Prior autologous stem cell transplant within 6 months of screening date. 7. Immunotherapy, chemotherapy, radiotherapy, or investigational therapy within 6 months prior to drug dosing. 8. Active central nervous system (CNS) involvement by lymphoma, including untreated symptomatic epidural disease. 9. Active uncontrolled infection. 10. Poorly controlled depressive symptoms and/ or currently under management for depression that is poorly controlled. 11. Significant disease or medical conditions, as assessed by the Investigator and Sponsor, that would substantially increase the risk benefit ratio of participating in the study. This includes, but is not limited to, acute myocardial infarction within the last 6 months, unstable angina, uncontrolled diabetes mellitus, significant active infections, and congestive heart failure New York Heart Association Class III-IV. 12. Second malignancy, except treated basal cell or localized squamous skin carcinomas, localized prostate cancer, or other malignancies for which subjects are not on active anti-cancer therapies and have had no evidence of active malignancy for at least 1 year. 13. History of major surgery within 3 weeks or minor surgery within 1 week of roflumilast administration. Major surgery includes, for example, any open or laparoscopic entry into a body cavity, or operative repair of fracture; minor surgery includes, for example, open surgical biopsy of palpable/superficial lymph node, or placement of vascular access device. 14. Other medical or psychiatric illnesses or organ dysfunction, which in the opinion of the investigator, would either compromise the subject's safety or interfere with the evaluation of the safety of the study agent. 15. Corrected QT interval (QTc) prolongation (defined as a QTc \>450 ms for males and \>470 ms for females -Fridericia's correction-) or other clinically significant ECG abnormalities as assessed by the investigator. 16. Baseline serum troponin above the upper limit of normal. 17. Baseline serum brain natriuretic peptide (BNP )above the age-adjusted upper limit of normal. 18. Baseline amylase above the upper limit of normal. 19. Subjects known to be HIV-positive must not have multi-drug resistant HIV infection, cluster of differentiation 4 (CD4) counts \< 150/µl or other concurrent AIDS-defining conditions. Serologic screening for HIV is required within the 6 months prior to study enrollment. 20. Subjects positive for Hepatitis B surface antigen (HBsAg) or Hepatitis C-virus ribonucleic acid (HCV RNA), unless both AST and ALT≤1.25 x ULN and there is no known history of chronic active hepatitis. Serologic screening for hepatitis B and C testing is required within the 6 months prior to study enrollment. 21. Subjects with moderate or severe liver impairment, as defined by a Child-Pugh class of B or C. 22. Women who are pregnant or breastfeeding. 23. Current use of any of the following medications: boceprevir, carbamazepine, ciprofloxacin, cobicistat, conivaptan, enzalutamide, fluvoxamine, itraconazole, ketoconazole, mitotane, phenytoin, posaconazole, rifampin, ritonavir, St. John's Wort, telaprevir, voriconazole, or zafirlukast. 24. Current use of non-nucleoside reverse transcriptase inhibitors (NNRTI) including efavirenz, rilpivirine, etravirine, delavirdine, nevirapine, and lersivirine.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Estimation of number of adverse events | Baseline up to 8 cycles (up to 24 weeks) | Estimation of adverse events (AE) and serious adverse events (SAE), graded according to the National Cancer Institute (NCI) - Common Terminology Criteria for Adverse Events (CTCAE) V5.0. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Estimation of complete response | Baseline up to 8 cycles (up to 24 weeks) | Estimation of complete response (CR) as defined by complete normalization of fluorodeoxyglucose positron emission tomography (FDG-PET) uptake (Deauville score of 1 to 3) of all target lesions |
| Estimation of progression-free survival (PFS) | Baseline up to 8 cycles (up to 24 weeks) | Estimation of progression-free survival (PFS) defined as the time from the date of registration until the date of disease progression or death as a result of any cause. |
Countries
United States
Contacts
CONTACTAdolfo Diaz Duque, MD
CONTACTRicardo E Aguiar, MD
PRINCIPAL_INVESTIGATORAdolfo E Diaz Duque, MD
The University of Texas Health Science Center at San Antonio
PRINCIPAL_INVESTIGATORRicardo Aguiar, MD
The University of Texas Health Science Center at San Antonio
Outcome results
None listed